ALMRAlamar Biosciences, Inc.

🇺🇸 US
31.50
USD
Analysis Scores
Lothien Robustness Score?
27/100
Weak
Neden bu skor?
Damodaran ?
17/100
DCF hesaplanamadı (faaliyet kârı veya nakit akışı eksik)
Dalio Risk ?
81/100
Piotroski ?
N/A
Yetersiz çeyrek verisi: 4 mevcut, en az 5 gerekli
Graham ?
Negatif HBK
Company is loss-making (EPS = -0.7091 TL) — Graham formula requires positive earnings
Active Metric?
1/4
Confidence?
48%
Lothien Robustness Summary
21/100
Lothien Sağlamlık: Çok Zayıf (21/100)
Temel göstergelerin çoğu olumsuz. Lothien sağlamlık skoru düşük seviyede. | Kısa Vade: Olumlu | Uzun Vade: Olumsuz | Pozitif: 3 | Negatif: 5 | Nötr: 2
Net Zarar
Son çeyrekte -$13M zarar açıklandı. Yatırımcı dikkatli olmalı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%-1.1). İstikrarlı seyir.
Yıllık Kâr Geriledi
Geçen yılın aynı dönemine göre net kâr %-66.8 düştü. Uzun vadede endişe verici.
3 Çeyrek Üst Üste Düşüş
Son 3 çeyrek üst üste kâr düşüyor. Aşağı trend endişe verici. Sonraki çeyreğe dikkat.
Yıllık Hasılat Büyümesi Güçlü
Yıllık hasılat %+68.5 arttı. Şirket büyüyor.
Güçlü Likidite
Cari oran 9.49x — kısa vadeli borçları rahat karşılıyor.
FAVÖK Büyümesi
FAVÖK çeyreklik %+273.0 arttı (-$12M → $21M). Operasyonel verimlilik artıyor.
Yüksek PD/DD
PD/DD: 7.22. Piyasa defter değerinin çok üstünde fiyatlıyor. Büyüme beklentisi primli.
Negatif ROE
ROE: %-15.5. Şirket özsermayesini eritiyor.
Lothien Sağlamlık Skoru: 27/100
Bileşik algoritma değerlendirmesine göre şirketin finansal yapısı zayıf görünüyor.

Data date 2026-11-10 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-11-10
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Çok Yüksek
143 days
Annual Volatility ?
%89.2
VaR 95% ?
%8.84
daily max loss
VaR 99% ?
%12.67
daily max loss
CVaR 95% ?
%10.35
expected loss (tail)
Max Drawdown ?
%38.3
05.10.2026 → 13.10.2026
Skewness ?
0.99
Parametrik%8.84
Historik%7.82
Cornish-Fisher%6.57
Return Distribution
Valuation
Potential?
-19.0%
ROIC ?
-20.8%
Debt Cycle?
Early Expansion
Balance Sheet Analysis? Q2026/9
Net kâr çeyreklik yatay seyrede (-13.3M USD, %-1.1)
Yıllık net kâr %-66.8 geriledi
Hasılat çeyreklik %+14.0 büyüdü (33.5M USD)
Yıllık hasılat büyümesi güçlü (%+68.5)
Brüt kâr marjı güçlü: %61.5
Brüt marj değişimi: %+1.3 puan
Net kâr marjı negatif: %-39.8 — zarar ediyor
FAVÖK çeyreklik %+273.0 büyüdü (20.6M USD)
FAVÖK marjı güçlü: %61.5
Cari oran güçlü: 9.49x — yükümlülükler rahat karşılanıyor
Nakit ve benzerleri: 121.5M USD
İşletme nakit akışı negatif: -14.7M USD
Serbest nakit akışı negatif: -15.2M USD — yatırımlar nakdi aşıyor
ROE negatif: %-4.4 — zarar var
ROA düşük: %-3.5
Toplam varlıklar: 378.0M USD (%-3.3)
Özkaynak: 303.7M USD (%-2.9)
İşletme kârı negatif: -15.1M USD — faaliyet zararı
Net işletme sermayesi pozitif: 284.2M USD
İşletme sermayesi değişimi: %-6.3
CAPEX: 463,000 USD (Hasılatın %1.4'i)
Son 6 çeyrek ardışık zarar
Fiyat TRAMA-99 üzerinde: %+5.2 — teknik trend olumlu
Destek seviyesi: TRAMA-99 = 29.95 USD
Likit varlık ağırlığı yüksek: Dönen varlıklar toplam varlıkların %84'i
Fundamental & Technical Analysis
Profitability
Net Profit Margin %-39.8
Net profit margin %-39.8 — loss period. Compared to previous quarter +5.1 point increase.
ROE - Return on Equity (TTM) %-15.5
ROE %-15.5 — negative return on equity.
EBITDA Margin %61.5
EBITDA margin %61.5 — operationally very efficient.
Gross Profit Margin %61.5
Gross profit per revenue %61.5. Strong pricing power.
Free Cash Flow Margin (TTM) %-61.3
TTM Free Cash Flow is %-61.3'i. Negative FCF — company consuming cash.
Valuation
P/B Ratio 7.22x Sector: 4.55x
PD/DD 7.22x — sector median's %59 above. Expensive book value.
Indebtedness
Current Ratio 9.49x
Current ratio 9.49x — current assets are 2x short-term liabilities. Very healthy liquidity.
Debt / Equity 0.17x
Low leverage — majority of assets financed by equity.
Interest Coverage -143.0x
Interest coverage -143.0x — critical level. Risk of difficulty in interest payments.
Growth
Revenue Growth (YoY) %+68.5
Revenue YoY %68.5 grew (2026/9) — strong growth. Sector expansion and/or market share increase.
Net Profit Growth (YoY) %-66.8
Loss %66.8 increased — losses deepening.
Score Explanations
Lothien Robustness
27/100
Weak robustness (27/100). Valuation metrics and/or debt profile are unfavorable; caution is needed.
Weak
Potential
-19.0%
Minus %19.0 expected value (25.57) vs current price comparison. 1/4 valuation models could be calculated. Model confidence %48.
Components: P/B target: 19.05
Damodaran Valuation
17/100
Very Weak
Dalio Risk Analysis
81/100
Low debt risk (81/100). Interest coverage ratio -143.0x — weak, fragile.
Leverage: 96/100 | Debt Service: 100/100 | Quality: 23/100
ROIC - Return on Capital
%-20.8
ROIC (%-20.8) cost of capital (11.1%) below → destroying value.
WACC: %11.1
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
—
Graham Intrinsic Value
—
Company is loss-making (EPS = -0.7091 TL) — Graham formula requires positive earnings
⚖️ Sector Comparison
P/B Ratio
7.22x vs 4.55x
Compared to sector %59 more expensive (by book value)
ROIC vs WACC
%-20.8 vs %11.1 WACC
ROIC 31.9 bps below cost of capital
Net Profit Margin (TTM)
%-51.3 vs %-40.6 EBITDA margin
TTM net profit margin %-51.3
TRAMA-99 Trend — Uptrend
Price (31.50), TRAMA-99 line's %5.2 above. Uptrend ongoing; monitor for TRAMA approach for trend change.
Price:: 31.50
TRAMA: 29.95
Difference: %+5.2
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
▲ içeriden alım · ▼ içeriden satım · ★ katalizör (haber-sezgisel) · ■ 13D aktivist · ■ 13G pasif — SEC Form 4 ~2 gün gecikmeli, yalnız yönetici/direktör/%10+ sahip; katalizör = haber-sezgisel; 13D/G = %5+ pay bildirimi ~5 iş günü gecikmeli.
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
Kurumsal Holdings — 13F (çeyreklik) ?

İçeriden Alım-Satım Akışı

Kim aldı, kim sattı, ne kadar

ALMR — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.